ACTEMRA® (tocilizumab)
ALECENSA® (alectinib)
Avastin® (bevacizumab)
COLUMVI™ (glofitamab-gxbm)
COTELLIC® (cobimetinib)
ENSPRYNG™ (satralizumab-mwge)
Erivedge® (vismodegib)
Evrysdi® (risdiplam)
GAVRETO® (pralsetinib)
GAZYVA® (obinutuzumab)
HEMLIBRA® (emicizumab-kxwh)
Herceptin® (trastuzumab)
Herceptin HYLECTA™ (trastuzumab and hyaluronidase-oysk)
KADCYLA® (ado-trastuzumab emtansine)
LUCENTIS® (ranibizumab injection)
LUNSUMIO™ (mosunetuzumab-axgb)
OCREVUS® (ocrelizumab)
PERJETA® (pertuzumab)
PHESGO™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf)
POLIVY® (polatuzumab vedotin-piiq)
Pulmozyme® (dornase alfa) Inhalation Solution
Rituxan® (rituximab) for Rheumatoid Arthritis (RA)
RITUXAN® (rituximab) for Oncology
Rituxan® (rituximab) for Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA) or Pemphigus Vulgaris (PV)
RITUXAN HYCELA® (rituximab/hyaluronidase human)
ROZLYTREK® (entrectinib)
SUSVIMO™ (ranibizumab injection)
TECENTRIQ® (atezolizumab)
VABYSMO® (faricimab-svoa)
VENCLEXTA® (venetoclax tablets)
XOLAIR® (omalizumab) for subcutaneous use
ZELBORAF® (vemurafenib)
Oncology
Ophthalmology
Rheumatology
Genentech co-pay programs provide financial assistance to eligible commerically insured patients to help with their co-pays, co-insurance or other out-of-pocket (OOP) costs. If your patients have commercial health insurance and meet other eligibility criteria, the Evrysdi Co-pay Program may be able to help them pay for Evrysdi.
To get started, call (833) 387-9734.
Eligibility criteria apply. Not valid for patients using federal or state government programs to pay for their Genentech medicine. Patients must be taking the Genentech medicine for an FDA-approved indication. Please visit the Co-pay Program website for the full list of Terms and Conditions.
For assistance, call (877) GENENTECH/(877) 436-3683
6 a.m.–5 p.m. PT, Monday through Friday
To enroll in MySMA Support, complete and submit the Evrysdi Start Form